Analyst firms · Morgan Stanley · RMD
Morgan Stanley RMD price target and rating history
ResMed Inc. (RMD) · Health Care
Morgan Stanley rates ResMed Inc. (RMD) Equal-Weight with a $230 price target, as of its latest action on Jun 17, 2026. It has published 4 rating actions on RMD since October 2023, including 1 upgrade and 1 downgrade. Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Morgan Stanley's $230 is 2% below that.
- Current rating
- Equal-Weight
- Price target
- $230
- Median target, all firms
- $235
- Actions on RMD
- 4
Morgan Stanley price target on RMD
Every Morgan Stanley rating on RMD
- Jun 17, 2026
- Mar 19, 2025
- Mar 19, 2025
- Oct 27, 2023
How other firms rate RMD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | Nov 2, 2026 | |
| RBC Capital Markets | Outperform | $262 | Sep 15, 2026 |
| Rothschild & Co Redburn | Neutral | $230 | Aug 19, 2026 |
| Citigroup | Neutral | $235 | Jul 13, 2026 |
| Morgan Stanley | Equal-Weight | $230 | Jun 17, 2026 |
| Robert W. Baird | Neutral | $275 | Dec 16, 2025 |
Questions about Morgan Stanley and RMD
- What is Morgan Stanley's price target for RMD?
- Morgan Stanley's latest stated price target for ResMed Inc. (RMD) is $230, from its action on Jun 17, 2026.
- What is Morgan Stanley's rating on RMD?
- Morgan Stanley rates RMD Equal-Weight, a neutral rating, as of Jun 17, 2026.
- When did Morgan Stanley last change its view on RMD?
- On Jun 17, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $230.
- How does Morgan Stanley's RMD target compare with other analysts?
- Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Morgan Stanley's $230 is 2% below that.
More RMD rating histories
- RBC Capital Markets13
- Citigroup8
- Robert W. Baird4
- CLSA5
- Wolfe Research3
- Needham3
- J.P. Morgan6
- BofA Securities3
All Morgan Stanley ratingsRMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.